Target intelligence / Profile preview

Colonic epithelial mucosal barrier

Molecular classification
Protein complex, Structural protein, Glycoprotein, Cell junction protein
01

Overview

The colonic epithelial tight junction and mucin complexes represent the integrated physical and chemical defense system of the large intestine (Groschwitz & Hogan, 2009). Tight junctions (TJs) are specialized intercellular protein networks composed of transmembrane proteins like claudins and occludin, which are anchored by cytosolic scaffold proteins such as zonula occludens-1 (ZO-1) to regulate paracellular permeability (Zihni et al., 2016). Complementing this, the mucin complex, dominated by the gel-forming glycoprotein MUC2, forms a dense, two-layered mucus blanket that segregates the luminal microbiota from the underlying epithelium (Johansson et al., 2011). In pathological states like ulcerative colitis and Crohn's disease, the degradation of the mucus layer and the disassembly of TJs lead to increased intestinal permeability, allowing the translocation of pathogens and pro-inflammatory antigens (Michielan & D'Incà, 2015). Therapeutic interventions aim to reinforce this barrier, with agents like larazotide acting as zonulin antagonists to stabilize TJs, and others like lubiprostone promoting mucosal repair and secretion (Gopalakrishnan et al., 2012). Maintaining the integrity of these complexes is crucial for preventing chronic immune activation and systemic inflammation.

Other names
Colonic epithelial tight junction and mucin complexesIntestinal epithelial barrierGut barrierIntestinal mucosal barrierTight junction-mucin unit
02

Mechanism of action

Restoration of the intestinal physical barrier through the modulation of tight junction proteins (e.g., claudins, occludin) and the stimulation of goblet cells to produce and secrete mucins (primarily MUC2) to prevent antigen translocation.

03

Biological functions

Barrier functionParacellular transport regulationMucosal protectionImmune exclusionHomeostasis
04

Disease associations

Inflammatory bowel diseaseCrohn's diseaseUlcerative colitisIrritable bowel syndromeCeliac diseaseIntestinal permeability disorders
05

Safety considerations

Risk of systemic absorption of luminal antigens if barrier modulation is imprecisePotential for malabsorption of essential nutrientsAlteration of the protective commensal microbiota nichePotential for unintended changes in cell signaling and polarity
06

Interacting drugs

Larazotide

5 more in the full profile.

07

Biomarkers

ZonulinFecal calprotectinClaudin-3Intestinal fatty acid-binding protein (I-FABP)MUC2 expression levels

Beyond the preview

Go deeper on Colonic epithelial mucosal barrier.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Colonic epithelial mucosal barrier.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call